PharmaResources (Shanghai) Co. Ltd. A (SHE:301230) — Stock Price
PharmaResources (Shanghai) Co. Ltd. A (SHE:301230) is currently trading at CN¥35.10 CNY, up 8.27% today. Over the past 52 weeks, shares have ranged between CN¥22.55 and CN¥65.76. This page tracks PharmaResources (Shanghai) Co. Ltd. A's live share price on the SHE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 301230 market cap overview.
PharmaResources (Shanghai) Co. Ltd. A (301230) Stock Price Chart — Daily History & Trading Volume
The chart below tracks PharmaResources (Shanghai) Co. Ltd. A's daily closing share price and trading volume on the SHE exchange over the past year, giving a clear view of recent price momentum and liquidity.
PharmaResources (Shanghai) Co. Ltd. A Income Statement — Revenue, Profit & Earnings by Year
PharmaResources (Shanghai) Co. Ltd. A's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | CN¥688.35 Million | CN¥544.47 Million | CN¥489.72 Million | CN¥478.88 Million | CN¥448.21 Million |
| Cost of Revenue | CN¥499.63 Million | CN¥414.54 Million | CN¥338.51 Million | CN¥302.30 Million | CN¥274.81 Million |
| Gross Profit | CN¥188.72 Million | CN¥129.93 Million | CN¥151.20 Million | CN¥176.58 Million | CN¥173.40 Million |
| Research & Development | CN¥37.15 Million | CN¥47.26 Million | CN¥37.34 Million | CN¥32.65 Million | CN¥17.14 Million |
| SG&A | CN¥23.04 Million | CN¥20.41 Million | CN¥24.13 Million | CN¥36.35 Million | CN¥23.84 Million |
| Total Operating Expenses | CN¥644.74 Million | CN¥547.62 Million | CN¥446.71 Million | CN¥412.01 Million | CN¥354.66 Million |
| Operating Income | CN¥43.62 Million | CN¥-3.15 Million | CN¥43.01 Million | CN¥66.88 Million | CN¥93.55 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | CN¥8.29 Million | CN¥9.28 Million | CN¥5.46 Million | CN¥4.79 Million | CN¥2.53 Million |
| Income Before Tax | CN¥28.32 Million | CN¥3.54 Million | CN¥36.76 Million | CN¥72.92 Million | CN¥86.23 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | CN¥34.29 Million | CN¥17.08 Million | CN¥37.62 Million | CN¥67.18 Million | CN¥73.58 Million |
PharmaResources (Shanghai) Co. Ltd. A Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes PharmaResources (Shanghai) Co. Ltd. A's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | CN¥1.31 Billion | CN¥1.32 Billion | CN¥1.49 Billion | CN¥1.30 Billion | CN¥557.81 Million |
| Total Current Assets | CN¥582.10 Million | CN¥554.32 Million | CN¥731.32 Million | CN¥936.53 Million | CN¥277.21 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | CN¥248.98 Million | CN¥251.77 Million | CN¥340.79 Million | CN¥10.65 Million | CN¥397.68K |
| Net Receivables | CN¥147.01 Million | CN¥98.65 Million | CN¥85.53 Million | CN¥82.04 Million | CN¥88.60 Million |
| Inventory | CN¥74.05 Million | CN¥69.04 Million | CN¥61.42 Million | CN¥51.09 Million | CN¥46.77 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | CN¥309.87 Million | CN¥283.73 Million | CN¥369.62 Million | CN¥188.38 Million | CN¥209.37 Million |
| Total Current Liabilities | CN¥172.21 Million | CN¥125.40 Million | CN¥191.22 Million | CN¥100.87 Million | CN¥128.67 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | CN¥1.00 Billion | CN¥1.03 Billion | CN¥1.12 Billion | CN¥1.11 Billion | CN¥348.44 Million |
| Retained Earnings | CN¥109.84 Million | CN¥149.48 Million | CN¥186.30 Million | CN¥192.06 Million | CN¥128.55 Million |
PharmaResources (Shanghai) Co. Ltd. A Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how PharmaResources (Shanghai) Co. Ltd. A generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | CN¥135.51 Million | CN¥80.86 Million | CN¥20.86 Million | CN¥99.29 Million | CN¥105.12 Million |
| Capital Expenditures | CN¥43.32 Million | CN¥109.40 Million | CN¥248.27 Million | CN¥123.97 Million | CN¥92.12 Million |
| Free Cash Flow | CN¥92.20 Million | CN¥-28.54 Million | CN¥-227.41 Million | CN¥-24.67 Million | CN¥13.01 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | CN¥54.04 Million | CN¥49.27 Million | CN¥38.82 Million | CN¥783.66K | CN¥782.22K |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | CN¥51.48 Million | CN¥49.07 Million | CN¥35.53 Million | CN¥28.40 Million | CN¥24.07 Million |
| Change in Cash | CN¥14.07 Million | CN¥-96.75 Million | CN¥-618.15 Million | CN¥657.89 Million | CN¥2.28 Million |
PharmaResources (Shanghai) Co. Ltd. A Earnings History — EPS Actual vs. Analyst Estimates
Track PharmaResources (Shanghai) Co. Ltd. A's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Sep 30, 2025 | 0.07 | — | — |
| Jun 30, 2025 | 0.09 | — | — |
| Apr 28, 2025 | 0.09 | — | — |
| Dec 31, 2024 | 0.01 | — | — |
| Sep 30, 2024 | -0.01 | — | — |
| Aug 27, 2024 | 0.09 | — | — |
| Apr 25, 2024 | 0.03 | — | — |
| Dec 31, 2023 | -0.06 | — | — |